{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:38:53Z","timestamp":1792607933417,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Cardiologie et d'Ang\u00e9iologie"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.ancard.2014.04.018","type":"journal-article","created":{"date-parts":[[2014,5,2]],"date-time":"2014-05-02T04:33:03Z","timestamp":1399005183000},"page":"222-227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Safety and effectiveness of the association ezetimibe-statin (E-S) versus high dose rosuvastatin after acute coronary syndrome: The SAFE-ES study"],"prefix":"10.1016","volume":"63","author":[{"given":"P.","family":"Deharo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pankert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Quilici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Grosdidier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Verdier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Morange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-C.","family":"Alessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-L.","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Cuisset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ancard.2014.04.018_bib0005","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","article-title":"ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)","volume":"33","author":"Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ancard.2014.04.018_bib0010","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52\u00a0countries (the INTERHEART study): case-control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ancard.2014.04.018_bib0015","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jama.1995.03530020049031","article-title":"Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five years follow-up of the seven countries study","volume":"274","author":"Verschuren","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.ancard.2014.04.018_bib0020","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1136\/bmj.303.6797.276","article-title":"Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations","volume":"303","author":"Chen","year":"1991","journal-title":"BMJ"},{"key":"10.1016\/j.ancard.2014.04.018_bib0025","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/j.jacc.2004.03.046","article-title":"Optimal low-density lipoprotein is 50 to 70mg\/dL. Lower is better and physiologically normal","volume":"43","author":"O\u2019Keefe","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ancard.2014.04.018_bib0030","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ancard.2014.04.018_bib0035","first-page":"232","article-title":"Ezetimibe: new perspectives in lipid lowering treatment","volume":"14","author":"Jankowski","year":"2007","journal-title":"Cardiol J"},{"key":"10.1016\/j.ancard.2014.04.018_bib0040","doi-asserted-by":"crossref","first-page":"99","DOI":"10.5551\/jat.14.99","article-title":"Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treathyperlipidemia","volume":"14","author":"Davis","year":"2007","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.ancard.2014.04.018_bib0045","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.amjcard.2008.01.041","article-title":"Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials","volume":"101","author":"Kashani","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ancard.2014.04.018_bib0050","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ahj.2004.03.052","article-title":"Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe coadministered with atorvastatin","volume":"148","author":"Stein","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.ancard.2014.04.018_bib0055","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S0828-282X(06)70319-1","article-title":"Efficacy and tolerability of ezetimibe 10mg\/day coadministered with statins in patients with primary hypercholesterolemeia who do not achieve target LDL-C while on statin monotherapy: a Canadian, multicentre, prospective study\u00a0\u2013\u00a0the Ezetrol Add-On Study","volume":"22","author":"Bissonnette","year":"2006","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.ancard.2014.04.018_bib0060","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1185\/030079907X210507","article-title":"Meta-analysis of the cholesterol- lowering effect of ezetimibe added to ongoing statin therapy","volume":"23","author":"Mikhailidis","year":"2007","journal-title":"Curr Med ResOpin"},{"key":"10.1016\/j.ancard.2014.04.018_bib0065","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","volume":"32","author":"Hamm","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ancard.2014.04.018_bib0070","doi-asserted-by":"crossref","first-page":"89C","DOI":"10.1016\/j.amjcard.2006.02.030","article-title":"Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force","volume":"97","author":"McKenney","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ancard.2014.04.018_bib0075","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0195-668X(02)00803-5","article-title":"Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial","volume":"24","author":"Melani","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ancard.2014.04.018_bib0080","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.amjcard.2006.10.022","article-title":"Efficacy and safety of rosuvastatin 40mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study)","volume":"99","author":"Ballantyne","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ancard.2014.04.018_bib0085","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1368-5031.2004.00289.x","article-title":"Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382\u00a0patients with primary hypercholesterolemia","volume":"58","author":"Davidson","year":"2004","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ancard.2014.04.018_bib0090","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1016\/j.jacc.2008.10.031","article-title":"Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial","volume":"52","author":"Fleg","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ancard.2014.04.018_bib0095","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1185\/03007995.2011.571239","article-title":"Comparative efficacy of the addition of ezetimibe to statin vs. statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis","volume":"27","author":"Mikhailidis","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ancard.2014.04.018_bib0100","unstructured":"Commission de transparence de la Haute Autorit\u00e9 de sant\u00e9. Available at: http:\/\/www.has-sante.fr\/portail\/jcms\/c_997109\/crestor-ct-8369. Accessed October 1, 2010."},{"key":"10.1016\/j.ancard.2014.04.018_bib0105","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering withstatins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ancard.2014.04.018_bib0110","doi-asserted-by":"crossref","first-page":"32C","DOI":"10.1016\/j.amjcard.2005.12.008","article-title":"Statin safety: an appraisal from the adverse event reporting system","volume":"97","author":"Davidson","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ancard.2014.04.018_bib0115","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJMoa0800742","article-title":"Simvastatin with or without ezetimibe in familial hypercholesterolemia","volume":"358","author":"Kastelein","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ancard.2014.04.018_bib0120","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report","volume":"106","author":"National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ancard.2014.04.018_bib0125","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1016\/j.amjcard.2008.07.063","article-title":"Impact of \u201cnuisance\u201d bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation","volume":"102","author":"Roy","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ancard.2014.04.018_bib0130","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1001\/jama.2011.522","article-title":"Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction","volume":"305","author":"Jernberg","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.ancard.2014.04.018_bib0135","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.amjcard.2007.09.099","article-title":"Efficacy and tolerability of fluvastatin XL 80mg alone, ezetimibe alone, and the combination of fluvastatin XL 80mg with ezetimibe in patients with a history of muscle-related side effects with other statins","volume":"101","author":"Stein","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ancard.2014.04.018_bib0140","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1345\/aph.10315","article-title":"Statin-fibrate combination therapy","volume":"35","author":"Shek","year":"2001","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ancard.2014.04.018_bib0145","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","article-title":"Early intensive vs. a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial","volume":"292","author":"De Lemos","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ancard.2014.04.018_bib0150","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"European Association for Cardiovascular Prevention & Rehabilitation","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ancard.2014.04.018_bib0155","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.ahj.2008.07.023","article-title":"Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe\/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes","volume":"156","author":"Cannon","year":"2008","journal-title":"Am Heart J"}],"container-title":["Annales de Cardiologie et d'Ang\u00e9iologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003392814000614?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003392814000614?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T22:11:24Z","timestamp":1565388684000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003392814000614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0003392814000614"],"URL":"https:\/\/doi.org\/10.1016\/j.ancard.2014.04.018","relation":{},"ISSN":["0003-3928"],"issn-type":[{"value":"0003-3928","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and effectiveness of the association ezetimibe-statin (E-S) versus high dose rosuvastatin after acute coronary syndrome: The SAFE-ES study","name":"articletitle","label":"Article Title"},{"value":"Annales de Cardiologie et d'Ang\u00e9iologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ancard.2014.04.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}